Skip to main content

Metagenomi Therapeutics, Inc.

MGX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001785279

In the last 90 days, Metagenomi Therapeutics, Inc. insiders filed 1 open-market purchase and 3 sales; 43 institutions reported holding it in 13F filings for Q2 2026, worth $7.45M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Metagenomi Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
1 filing
1 insider, $23.4K in total
Open-market sells
3 filings
3 insiders, $5.11K in total
Insiders trading
4
Net value
+$18.3K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Metagenomi Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Metagenomi Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Reid LaurenceDirector20,000Sep 11, 20262
Wein MatthewSee Remarks126,133Sep 10, 20266
Irish JianSee Remarks375,393Sep 10, 20266
Wapnick PamelaChief Financial Officer206,580Sep 10, 20266
Bjerkholt EricDirector–Jun 11, 20261
Dere Willard HDirector–Jun 11, 20261
Eckhardt JuergenDirector–Jun 11, 20261
Thomas Brian C.Director2,510,960Dec 8, 20252
Noonberg Sarah B.Chief Medical Officer109,135Jun 9, 20250
Borges LuisChief Scientific Officer69,316Apr 3, 20240
Bernales SebastianDirector1,896,445IndirectApr 3, 20240
Harnest SimonSee Remarks122,664Apr 3, 20240
Delaney SimrenSee Remarks93,892Apr 3, 20240
Bayer Aktiengesellschaft10% Owner4,050,997Feb 15, 20240
Bayer Healthcare LLC10% Owner4,050,997Feb 15, 20240
Bayer World Investments B.V.10% Owner4,050,997Feb 15, 20240
Bayer US Holding LP10% Owner4,050,997Feb 15, 20240
Novo Holdings A/S10% Owner1,739,175Feb 15, 20240

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 11, 2026 (view filing)7:51 PM ETSep 92 daysReid LaurenceDirectorPPurchase+20.0K$1.17+$23.4KNew position20.0K after2 lots
Sep 10, 2026 (view filing)3:47 PM ETSep 82 daysWein MatthewSee RemarksSSale−358$1.16−$414.71−0.3%126.1K after
Sep 10, 2026 (view filing)3:40 PM ETSep 82 daysIrish JianSee RemarksSSale−2.14K$1.16−$2.48K−0.6%375.4K after
Sep 10, 2026 (view filing)3:34 PM ETSep 82 daysWapnick PamelaChief Financial OfficerSSale−1.91K$1.16−$2.21K−0.9%206.6K after
Jun 10, 2026 (view filing)Jun 55 daysLateWapnick PamelaChief Financial OfficerSSale−2.88K$1.30−$3.75K−1.4%208.5K after
Jun 10, 2026 (view filing)Jun 55 daysLateIrish JianSee RemarksSSale−3.74K$1.30−$4.86K−1.0%377.5K after
Jun 10, 2026 (view filing)Jun 55 daysLateWein MatthewSee RemarksSSale−558$1.30−$725.4−0.4%126.5K after
Mar 9, 2026 (view filing)Mar 54 daysWapnick PamelaChief Financial OfficerSSale−1.58K$1.60−$2.53K−0.8%187.4K after
Mar 9, 2026 (view filing)Mar 54 daysWein MatthewSee RemarksSSale−482$1.60−$771.2−0.4%114.5K after
Mar 9, 2026 (view filing)Mar 54 daysIrish JianChief Executive OfficerSSale−1.61K$1.60−$2.57K−0.5%333.8K after
Dec 8, 2025 (view filing)Dec 53 daysThomas Brian C.DirectorSSale−3.83K$1.77−$6.78K−0.2%2.51M after
Dec 8, 2025 (view filing)Dec 53 daysWein MatthewSee RemarksSSale−199$1.77−$352.23−0.2%115.0K after
Dec 8, 2025 (view filing)Dec 53 daysWapnick PamelaChief Financial OfficerSSale−1.58K$1.77−$2.79K−0.8%189.0K after
Dec 8, 2025 (view filing)Dec 53 daysIrish JianChief Executive OfficerSSale−1.60K$1.77−$2.84K−0.3%563.8K after
Dec 1, 2025 (view filing)Sep 587 daysLateThomas Brian C.DirectorSSale−2.70K$1.81−$4.89K−0.1%2.51M after
Dec 1, 2025 (view filing)Sep 587 daysLateWapnick PamelaChief Financial OfficerSSale−1.58K$1.81−$2.85K−2.2%70.5K after
Dec 1, 2025 (view filing)Sep 587 daysLateIrish JianChief Executive OfficerSSale−1.60K$1.81−$2.90K−0.5%316.9K after
Dec 1, 2025 (view filing)Sep 587 daysLateWein MatthewSee RemarksSSale−199$1.81−$360.19−1.0%19.2K after
Jun 9, 2025 (view filing)Jun 63 daysWein MatthewSee RemarksSSale−199$1.75−$348.25−1.2%16.7K after
Jun 9, 2025 (view filing)Jun 63 daysNoonberg Sarah B.Chief Medical OfficerSSale−5.24K$1.75−$9.17K−4.6%109.1K after
Jun 9, 2025 (view filing)Jun 63 daysWapnick PamelaChief Financial OfficerSSale−1.58K$1.75−$2.76K−2.1%72.1K after
Jun 9, 2025 (view filing)Jun 63 daysThomas Brian C.Chief Executive OfficerSSale−10.8K$1.75−$18.9K−0.4%2.52M after
Jun 9, 2025 (view filing)Jun 63 daysIrish JianSee RemarksSSale−6.39K$1.75−$11.2K−2.0%315.5K after
Mar 7, 2025 (view filing)Mar 52 daysWein MatthewSee RemarksSSale−930$1.87−$1.74K−8.9%9.47K after
Mar 7, 2025 (view filing)Mar 52 daysWapnick PamelaChief Financial OfficerSSale−1.81K$1.87−$3.38K−2.9%59.7K after
Dec 6, 2024 (view filing)Dec 51 dayWapnick PamelaChief Financial OfficerSSale−1.56K$1.86−$2.90K−2.5%61.5K after
Sep 6, 2024 (view filing)Sep 51 dayWapnick PamelaChief Financial OfficerSSale−6.26K$2.88−$18.0K−9.0%63.1K after
Feb 15, 2024 (view filing)Feb 9-136 daysLateNovo Holdings A/S10% OwnerPPurchase+900.0K$14.47+$13.0M+107.2%1.74M after2 lots